-
Japan win marathon penalty shootout to set up South Korea gold-medal clash
-
US reports firm Q2 economic growth, inflation steady
-
Djokovic grinds out opening-round win at China Open
-
Energy costs spark inflation surge across Europe
-
Northern Ireland police probe blockade of disputed parade
-
Parma appoint Italy World Cup winner Gilardino
-
UK PM Burnham reopens divisive debate on rejoining EU
-
West Indies pile up record 405-7 in second ODI against India
-
Man City future in doubt after guilty verdict
-
Romanian parliament rejects pro-EU PM candidate amid political deadlock
-
'Do something,' begs Iranian woman after death sentence over protests
-
Passenger on rerouted flydubai flight says pilot tried to crash plane
-
China extends 52-year unbeaten record as Games organisers say sorry
-
Russia targets Kyiv power supply as freezing winter approaches
-
In Manchester, people say City scandal is 'shame for football'
-
Haze pushes Kuala Lumpur, Singapore into world's most polluted cities
-
Stocks lacklustre as inflation data weighs on sentiment
-
Dangote's $16bn Kenya refinery 'new chapter' for Africa
-
Israel-bound plane rerouted, pilots wounded in reported fight
-
Ireland coach Hallgrimsson confirms second Israel game will go ahead
-
Truth commission on Sweden's Sami people seeks redress
-
Swift concert attack plan convict fails to get Disney damages
-
Energy costs spark inflation surges in France, Italy
-
Ocon to leave Haas at end of F1 season
-
South Korea break China hearts to reach Asian Games football final
-
Indonesia razes poolside prison 'villas' where whisky, TVs seized
-
Eala storms into Asian Games semi-finals to thrill adoring fans
-
Japan court rules human voice is protected in TikTok AI case
-
Turkey freezes ex-minister's assets as fund crisis grows
-
French inflation jumps to 3% in September on energy costs
-
What we know about the North Korean POW dispute
-
South Korea score late to reach Asian Games football final
-
Most equities rise after oil price plunge, US data in focus
-
Tom Kim defies jet-lag, Kho cards ace as Asian Games golf begins
-
Polar oceans transformed as warming melts ice habitats: research
-
Thai teen rocker Nene aims to tour, write music... and return to school
-
Lost shark becomes viral star in South Korea
-
Ivory Coast clamps down on harmful illegal gold rush
-
Dangote to launch $16bn refinery in Kenya
-
Nagoya mayor says sorry for Asian Games 'inconveniences'
-
North Korean leader 'extremely obese': Seoul spy agency
-
G20 trade officials meet under shadow of tariffs, overcapacity
-
Yankees and pope-backed White Sox start MLB playoffs with wins
-
India's fat dog vote goes viral
-
Malaysia's ex-PM Mahathir in hospital for observation
-
Asian Games crowds in spotlight as 998 see hosts in 50,000 stadium
-
'No limits': Marathon world record holder Sawe chasing history
-
The eight stadiums for the 2027 Rugby World Cup
-
Countdown begins to biggest-ever Rugby World Cup
-
Thieves swipe drugs under nose of Fiji police, swap with flour
Canada health authority approves Pfizer's anti-Covid pill
Canada's health authority said Monday it has approved Pfizer's anti-Covid pill, Paxlovid, for adults at high risk of progressing to serious disease.
The oral treatment was approved after an "expedited review," Health Canada said in a statement on its website, adding that it would continue to monitor its safety and effectiveness.
"No drug, including PAXLOVID TM, is a substitute for vaccination," the statement added.
The drug, which comprises two types of tablet, is the first Covid-19 therapy which can be taken at home, and is potentially a huge step towards ending the pandemic.
"Today's announcement is particularly important as access to easy-to-use treatments could help to reduce the severity of Covid-19 in adults who become newly infected and are at high-risk of progressing to serious illness," said Theresa Tam, Canada's chief public health officer.
The approval comes as Canada, like many countries, has been struggling to contain the Omicron variant of Covid-19.
The French-speaking province of Quebec recently announced it would levy a tax on the unvaccinated, arguing they impose a burden on everyone else.
Paxlovid has so far been authorized in a handful of countries including the United States and Israel, while the European Union has allowed member states to use it ahead of formal approval as an emergency measure against Omicron.
Unlike vaccines, it does not target the ever-evolving spike protein which the coronavirus uses to invade cells.
It should therefore in theory be more variant-proof, and the company has said preliminary lab studies have backed up that hypothesis.
A.Gasser--BTB